Bruker Corporation (BRKR)

Bruker reported an actual EPS of -0.410 USD for Q3 2025. Preliminary revenue for Q2 2025 was in the range of $795 - $798 million, with a decline in non-GAAP organic revenue. Bruker adjusted its revenue expectations for fiscal year 2025 and announced a cost reduction strategy. The company announced a public offering of $600 million in Mandatory Convertible Preferred Stock. Bruker consolidated its ownership of TOFWERK AG. Bruker announced several significant European orders for high-performance magnetic resonance systems. Bruker announced the successful installation of its 1.2 GHz Nuclear Magnetic Resonance (NMR) spectrometer. Bruker launched its most advanced benchtop vacuum Fourier-Transform Infrared (FT-IR) spectrometer, the VERTEX NEO Ultra.

Specific demand seasonality data for Bruker Corp.'s products is not readily available. However, the company operates in markets that can experience fluctuations, such as academic, government, and biopharma. Bruker anticipates a partial recovery in demand by 2026 and expects to benefit from a healthy backlog and recovery in key markets.

Bruker Corp. is an American manufacturer of scientific instruments and diagnostic tests for industries like life sciences, pharmaceuticals, and biotechnology. The company's business is structured around segments like BSI BioSpin, BSI CALID, BSI Nano, and Supercon Technologies, with BSI CALID being a significant revenue generator. Its product portfolio includes NMR spectroscopy equipment, mass spectrometry systems, X-ray devices, infrared and Raman spectroscopy tools, atomic force microscopy, preclinical imaging systems, and DNA test strips.

Bruker Corporation has a significant global presence with over 90 locations worldwide and more than 11,000 employees. The majority of its revenue comes from the United States. In Q3 2024, the Americas saw low-single-digit growth, Asia-Pacific (excluding China) experienced double-digit growth, while China faced a low double-digit decline. Europe also saw a low single-digit decline, and EMEA showed mid-teen percentage growth year-over-year.

Bruker Corporation has a strong reputation as a leading global provider of scientific instruments and solutions, recognized for its commitment to scientific excellence and customer support. The company has demonstrated its commitment to innovation through product launches and acquisitions. While broader corporate reputation has faced challenges, no specific negative events have directly impacted Bruker's brand reputation.

Institutional investors hold 80.00% of Bruker's shares, with key shareholders including T. Rowe Price, Vanguard, and BlackRock. Frank H. Laukien, the CEO, is the largest individual stockholder, holding 26.69% ownership as of April 1, 2025. The Laukien family also remains a principal insider holder.